Has Patricia Rich, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,071,378 in general payments to Patricia Rich, MD across 463 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Patricia Rich, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Patricia Rich, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Patricia Rich, MD

Medical Oncology · Atlanta, GANPI 1386750149

Payments from drug & device makers

$1,071,378in general payments, 2019–2025

Across 463 payments — averaging $2313.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$467K
Ipsen Bioscience Inc.$130K
Eli Lilly$93K
AbbVie$89K
AstraZeneca$61K
Genentech, Inc.$57K
plus $175K from 46 others

$2,029in research payments, 2019–2025

Across 2 payments — averaging $1014.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$2K

What the payments were for

Consulting fees$1,84518%
Speaking & faculty fees$1,63216%
Travel & lodging$5886%
Food & beverage$5,87758%
Education$2252%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	68	$467,275
Ipsen Bioscience Inc.	55	$130,075
Eli Lilly	2	$92,520
AbbVie	7	$89,370
AstraZeneca	33	$60,828
Genentech, Inc.	14	$56,682
F. Hoffmann-la Roche AG	12	$55,757
E.r. Squibb & Sons, L.L.C.	25	$48,511
EMD Serono, Inc.	20	$46,126
Sanofi US Services Inc.	2	$12,494
Spectrum Pharmaceuticals Inc.	2	$2,726
Sanofi	4	$1,896
Coherus Oncology, Inc.	8	$1,867
Novartis	46	$1,058
Intuitive Surgical	2	$588
Amgen	20	$403
Eisai Inc.	12	$326
Regeneron Healthcare Solutions, Inc.	10	$313
Astellas Pharma US Inc	11	$305
Genentech USA, Inc.	19	$265
Johnson & Johnson	11	$208
Boehringer Ingelheim	10	$194
Medtronic	2	$154
Jazz Pharmaceuticals Inc.	2	$142
Novocure Inc.	1	$121
Bristol Myers Squibb	8	$121
Seagen Inc.	6	$102
Lilly USA, LLC	5	$93
Bayer	5	$80
Gilead	4	$77
Kyowa Kirin, Inc.	4	$59
Exelixis Inc.	4	$55
Taiho Oncology, Inc.	3	$53
Takeda Pharmaceuticals U.S.A., Inc.	3	$50
Puma Biotechnology, Inc.	2	$45
Tersera Therapeutics LLC	2	$42
Deciphera Pharmaceuticals Inc.	2	$39
Array Biopharma Inc	2	$37
Healthmyne, Inc.	1	$35
GSK	1	$34
Ipsen Biopharmaceuticals, Inc	2	$28
Blueprint Medicines Corporation	1	$28
Tempus AI, Inc	1	$27
Karyopharm Therapeutics Inc.	1	$27
ADC Therapeutics America, Inc.	1	$24
Blue Earth Diagnostics	1	$23
Sanofi-aventis U.S. LLC	1	$22
Beigene USA, Inc.	1	$18
Pharmacyclics LLC, An Abbvie Company	1	$16
Tesaro, Inc.	1	$16
Daiichi Sankyo Inc.	1	$13
Pfizer	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,071,378 in reported general payments places this provider in the 80th percentile of 68 medical oncology providers in Georgia.

See all medical oncology providers in Georgia →

Medicare billing

Part B allowed, 2024

$34,875

Medicare patients

123

Services billed

505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dexamethasone	121	$1,631
Prochlorperazine Maleate	93	$1,089
Ondansetron Hcl	99	$1,035
Lidocaine-PrilocaineLidocaine/Prilocaine	59	$769
Ondansetron OdtOndansetron	28	$464
Gabapentin	18	$187
Potassium Chloride	15	$111
Levothyroxine Sodium	11	$63
Folic Acid	17	$61
Lorazepam	13	$12

Paid to pharmacies, not to this prescriber.

Other medical oncology in Atlanta

Suresh RamalingamAtlanta$10.5M
Jonathan KaufmanAtlanta$7.7M
Nabil SabaAtlanta$2.8M
Olumide GbolahanAtlanta$2.7M
Bradley CarthonAtlanta$2.7M
Amelia LangstonAtlanta$2.1M
Ragini KudchadkarAtlanta$2M
Nisha JosephAtlanta$1.7M
Eyal MeiriAtlanta$1.1M
Dong ShinAtlanta$406K

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →